Загрузка...
Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases
BACKGROUND: Sunitinib, an oral multitarget tyrosine kinase inhibitor and standard first-line treatment for metastatic renal cell carcinoma (mRCC), is generally administered on a 6-week schedule (4 weeks on/2 weeks off). However, drug toxicity often leads to temporary treatment interruption, resultin...
Сохранить в:
| Опубликовано в: : | BMC Res Notes |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4289163/ https://ncbi.nlm.nih.gov/pubmed/25471941 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-7-872 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|